{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:31:04Z","timestamp":1792074664059,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2002,2]]},"DOI":"10.1053\/sonc.2002.31534","type":"journal-article","created":{"date-parts":[[2002,8,24]],"date-time":"2002-08-24T23:46:10Z","timestamp":1030232770000},"page":"132-138","source":"Crossref","is-referenced-by-count":13,"special_numbering":"S4","title":["Bisphosphonates in the treatment of bone metastases"],"prefix":"10.1053","volume":"29","author":[{"given":"Rebecca S","family":"Finley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/sonc.2002.31534_BIB1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/jbmr.5650070814","article-title":"Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridization","volume":"7","author":"Vargas","year":"1992","journal-title":"J Bone Miner Res"},{"key":"10.1053\/sonc.2002.31534_BIB2","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","article-title":"Current use of bisphosphonates in oncology. International Bone and Cancer Study Group","volume":"16","author":"Body","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.31534_BIB3","first-page":"48","article-title":"Insulin-like growth factor receptor expression and function in human breast cancer","volume":"50","author":"Cullen","year":"1990","journal-title":"Cancer Res"},{"key":"10.1053\/sonc.2002.31534_BIB4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1634\/theoncologist.5-6-463","article-title":"Management of bone metastases","volume":"5","author":"Coleman","year":"2000","journal-title":"Oncologist"},{"issue":"suppl 1","key":"10.1053\/sonc.2002.31534_BIB5","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z","article-title":"Overview of bisphosphonates","volume":"80","author":"Rogers","year":"1997","journal-title":"Cancer"},{"key":"10.1053\/sonc.2002.31534_BIB6","first-page":"389","article-title":"Antiresorptive dose-response relationships across three generations of bisphosphonates","volume":"15","author":"Sietsema","year":"1989","journal-title":"Drugs Exp Clin Res"},{"key":"10.1053\/sonc.2002.31534_BIB7","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","article-title":"Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound","volume":"9","author":"Green","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.1053\/sonc.2002.31534_BIB8","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","article-title":"BM 21.0955, a potent new bisphosphonate to inhibit bone resorption","volume":"6","author":"Muhlbauer","year":"1991","journal-title":"J Bone Miner Res"},{"key":"10.1053\/sonc.2002.31534_BIB9","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo","volume":"10","author":"Hughes","year":"1995","journal-title":"J Bone Miner Res"},{"key":"10.1053\/sonc.2002.31534_BIB10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2141.1997.2713086.x","article-title":"Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity","volume":"98","author":"Shipman","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1053\/sonc.2002.31534_BIB11","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1172\/JCI114459","article-title":"Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro","volume":"85","author":"Carano","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1053\/sonc.2002.31534_BIB12","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1172\/JCI118841","article-title":"Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro","volume":"98","author":"van der Pluijm","year":"1996","journal-title":"J Clin Invest"},{"issue":"suppl 1","key":"10.1053\/sonc.2002.31534_BIB13","first-page":"S188","article-title":"Bisphosphonates inhibit breast cancer cell proliferation and induce cell apoptosis","volume":"14","author":"Fromigue","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.1053\/sonc.2002.31534_BIB14","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","article-title":"Bisphosphonates induce apoptosis in human breast cancer cell lines","volume":"82","author":"Senaratne","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1053\/sonc.2002.31534_BIB15","first-page":"2949","article-title":"Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases","volume":"60","author":"Boissier","year":"2000","journal-title":"Cancer Res"},{"key":"10.1053\/sonc.2002.31534_BIB16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00666208","article-title":"Osteolytic bone metastasis in breast cancer","volume":"32","author":"Yoneda","year":"1994","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/sonc.2002.31534_BIB17","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1172\/JCI119435","article-title":"Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2","volume":"99","author":"Yoneda","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1053\/sonc.2002.31534_BIB18","first-page":"3551","article-title":"Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice","volume":"55","author":"Sasaki","year":"1995","journal-title":"Cancer Res"},{"key":"10.1053\/sonc.2002.31534_BIB19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jbmr.5650090211","article-title":"Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system","volume":"9","author":"Hall","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.1053\/sonc.2002.31534_BIB20","first-page":"221","article-title":"Experimental findings on the osteoprotective potential of bisphosphonates against bone metastases and tumor-induced osteopathy: A pleading for an early and preventive administration","author":"Krempien","year":"1996"},{"key":"10.1053\/sonc.2002.31534_BIB21","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/BF00390862","article-title":"A model of localized osteolysis induced by the MBT-2 tumor in mice and its responsiveness to etidronate disodium","volume":"113","author":"Nemoto","year":"1987","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1053\/sonc.2002.31534_BIB22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/1097-0142(19930701)72:1<91::AID-CNCR2820720118>3.0.CO;2-2","article-title":"Prophylactic treatment of skeletal metastases, tumor-induced osteolysis, and hypercalcemia in rats with the bisphosphonate Cl2MBP","volume":"72","author":"Krempien","year":"1993","journal-title":"Cancer"},{"key":"10.1053\/sonc.2002.31534_BIB23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000226528","article-title":"Protective effects of a prophylactic treatment with the bisphosphonate 3-amino-1-hydroxypropane-1,1-bisphosphonic acid on the development of tumor osteopathies in the rat: Experimental studies with the Walker carcinosarcoma 256","volume":"45","author":"Krempien","year":"1988","journal-title":"Oncology"},{"key":"10.1053\/sonc.2002.31534_BIB24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF00402773","article-title":"Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat","volume":"111","author":"Wingen","year":"1986","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1053\/sonc.2002.31534_BIB25","first-page":"5452","article-title":"Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats","volume":"53","author":"Kostenuik","year":"1993","journal-title":"Cancer Res"},{"key":"10.1053\/sonc.2002.31534_BIB26","first-page":"575a","article-title":"Double-blind placebo-controlled trial of ibandronate in breast cancer metastatic to bone","volume":"18","author":"Body","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 1","key":"10.1053\/sonc.2002.31534_BIB27","first-page":"586","article-title":"Phase I clinical study of a new bisphosphonate, zoledronate (CGP-42446), in patients with osteolytic bone metastases","volume":"88","author":"Berenson","year":"1998","journal-title":"Blood"},{"key":"10.1053\/sonc.2002.31534_BIB28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.31534_BIB29","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"10.1053\/sonc.2002.31534_BIB30","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(87)92555-4","article-title":"Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment","volume":"2","author":"van Holten-Verzantvoort","year":"1987","journal-title":"Lancet"},{"key":"10.1053\/sonc.2002.31534_BIB31","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1200\/JCO.1996.14.9.2552","article-title":"Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomised controlled trial. The Aredia Multinational Cooperative Group","volume":"14","author":"Conte","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.31534_BIB32","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"issue":"suppl 5","key":"10.1053\/sonc.2002.31534_BIB33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/02841869609083974","article-title":"Efficacy of pamidronate in breast cancer with bone metastases. A randomized double-blind placebo controlled multicenter study","volume":"35","author":"Hultborn","year":"1996","journal-title":"Acta Oncol"},{"key":"10.1053\/sonc.2002.31534_BIB34","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.31534_BIB35","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","article-title":"Current use of bisphosphonates in oncology. International Bone and Cancer Study Group","volume":"16","author":"Body","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.31534_BIB36","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Avedia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/sonc.2002.31534_BIB37","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Avedia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.31534_BIB38","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/sonc.2002.31534_BIB39","first-page":"1082","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases","volume":"88","author":"Lipton","year":"2000","journal-title":"Long term follow-up of two randomized, placebo-controlled trials. Cancer"},{"key":"10.1053\/sonc.2002.31534_BIB40","unstructured":"Anonymous. Zometa. Zoledronic acid Product Monograph. Protocol 007. Data on file. Novartis Pharmaceuticals AG, Basel, Switzerland"},{"key":"10.1053\/sonc.2002.31534_BIB41","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.1991.9.8.1397","article-title":"Effect of daily etidronate on the osteolysis of multiple myeloma","volume":"9","author":"Belch","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.31534_BIB42","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0140-6736(90)90452-B","article-title":"Use of pamidronate for multiple myeloma osteolytic lesions","volume":"335","author":"Man","year":"1990","journal-title":"Lancet"},{"key":"10.1053\/sonc.2002.31534_BIB43","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/sonc.2002.31534_BIB44","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/jnci\/90.21.1601","article-title":"Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer","volume":"90","author":"Goldhirsch","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/sonc.2002.31534_BIB45","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial","volume":"19","author":"Saarto","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.31534_BIB46","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.2000.18.6.1378","article-title":"American Society of Clinical Oncology Guidelines on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Expert Panel","volume":"18","author":"Hillner","year":"2000","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775402501214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775402501214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T21:55:56Z","timestamp":1555019756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775402501214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["S0093775402501214"],"URL":"https:\/\/doi.org\/10.1053\/sonc.2002.31534","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}